Table 2.

The use of baricitinib in treating autoimmune bullous disease.

	Age/ gender	Types of AIBD	Complica-tion	Previous therapies	Treatment	Efficacy of initial use of JAK inhibitors	Tapering of JAK inhibitors	Efficacy of maintenance treatment	AE	Relapse
Sarny et al., 2018 (43)	43/M	MMP	Psoriasis	MTX, CP, MMF, RTX, IVIG, ADM, PSL	Baricitinib 4 mg/d, MTX 25mg/w, PSL 6mg/d	The disease was improved within two months	Baricitinib was stopped due to decreasing of neutrophils for 2 weeks. Subsequently, baricitinib was taken each day.	Progression of end-stage MMP seemed stopped.	None	NA
Burningham et al., 2022 (44)	69/F	MMP	T2DM, breast cancer	TCS, MTX, prednisone, IVIG, RTX, MMF, CP.	Baricitinib 2 mg/d, prednisone, MTX 12.5 mg/w, then increased to 20 mg/w.	Conditions of ocular, oral and esophageal were improved.	NA	The patient continued to improved.	NA	NA.
Xiao et al., 2022 (45)	83/M	BP	Psoriasis, stage III HT, postoperative lung cancer	Compound glycyrrhizin, TCS	Baricitinib 4 mg/d, Halometasone cream 0.5g/d	Skin lesions and pruritus improved significantly.	Baricitinib was halved and continued for 12 weeks	Both bullous and psoriatic lesions were in complete remission	None	A few new blisters were noted but faded away 3 days later.
Moussa et al., 2022 (46)	36/M	LPP	NA	TCS, SCS, MTX, AZP, ciclosporin, doxycycline, PUVA	Baricitinib 6.8 mg/d.	A significant improvement in pruritus and LPP lesions.	Baricitinib reduced to 3.4 mg/d	LPP almost completely relieved	NA	NA

AIBD, autoimmune bullous disease; JAKi, janus kinase inhibitors; AE, adverse effect; MMP, mucous membrane pemphigoid; BP, bullous pemphigoid; LPP, Lichen planus pemphigoides; M, male; F, female; MTX, methotrexate; CP, cyclophosphamide; MMF, mycophenolate mofetil; AZP, azathioprine; RTX, rituximab; IVIG, intravenous immunoglobulin; ADM, Adalimumab; PSL, prednisolone; TCS, topical corticosteroids; SCS, systemic corticosteroids; PUVA, psoralen plus ultraviolet A; T2DM, type 2 diabetes mellitus; HT, hypertension; NA, not available; mg/d, mg/day; mg/w, mg/week.